📣 VC round data is live. Check it out!

IQVIA Valuation Multiples

Discover IQVIA's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Veeva, GE HealthCare, Roper Technologies, Sartorius and more.

IQVIA Overview

About IQVIA

Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.


Founded

2016

HQ

United States

Employees

93.0K

Website

iqvia.com

Financials (LTM)

Revenue: $17B
EBITDA: $4B

EV

$45B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

IQVIA Financials

IQVIA reported last 12-month revenue of $17B and EBITDA of $4B.

In the same LTM period, IQVIA generated $6B in gross profit, $4B in EBITDA, and $2B in net income.

Revenue (LTM)


IQVIA P&L

In the most recent fiscal year, IQVIA reported revenue of $16B and EBITDA of $4B.

IQVIA is profitable as of last fiscal year, with gross margin of 33%, EBITDA margin of 23%, and net margin of 13%.

See analyst estimates for IQVIA
LTMLast FY202320242025202620272028
Revenue$17B$16B$15B$15B$16B
Gross Profit$6B$5B$5B$5B$5B
Gross Margin33%33%35%35%33%
EBITDA$4B$4B$3B$3B$3B
EBITDA Margin23%23%22%22%21%
EBIT Margin19%19%14%15%14%
Net Profit$2B$2B$1B$1B$1B
Net Margin13%13%9%9%8%
Net Debt-$14B---

Financial data powered by Morningstar, Inc.

IQVIA Stock Performance

IQVIA has current market cap of $31B, and enterprise value of $45B.

Market Cap Evolution


IQVIA's stock price is $186.82.

IQVIA share price increased by 2.5% in the last 30 days, and by 18.5% in the last year.

IQVIA has an EPS (earnings per share) of $12.39.

See more trading valuation data for IQVIA
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$45B$31B2.5%2.5%9.5%18.5%$12.39

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

IQVIA Valuation Multiples

IQVIA trades at 2.7x EV/Revenue multiple, and 11.6x EV/EBITDA.

See NTM and 2027E valuation multiples for IQVIA

EV / Revenue (LTM)


IQVIA Financial Valuation Multiples

As of June 2, 2026, IQVIA has market cap of $31B and EV of $45B.

IQVIA has a P/E ratio of 14.8x.

LTMLast FY202320242025202620272028
EV/Revenue2.7x2.8x3.0x2.9x2.8x
EV/EBITDA11.6x11.9x13.9x13.1x13.0x
EV/EBIT13.9x14.2x21.9x19.9x19.7x
EV/Gross Profit8.1x8.3x8.6x8.4x8.3x
P/E14.8x15.1x23.0x22.7x22.9x
EV/FCF20.8x21.0x30.1x21.4x22.0x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified IQVIA Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

IQVIA Margins & Growth Rates

IQVIA grew revenue by 6% and EBITDA by 6% in the last fiscal year.

In the most recent fiscal year, IQVIA reported gross margin of 33%, EBITDA margin of 23%, and net margin of 13%.

See estimated margins and future growth rates for IQVIA

IQVIA Margins

Last FY202420252026202720282029
Gross Margin33%35%33%33%
EBITDA Margin23%22%21%23%
EBIT Margin19%15%14%19%
Net Margin13%9%8%13%
FCF Margin13%14%13%13%

IQVIA Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth6%3%6%6%
Gross Profit Growth5%3%1%5%
EBITDA Growth6%6%0%15%
EBIT Growth6%10%1%47%
Net Profit Growth5%1%(1%)59%
FCF Growth3%41%(3%)8%

Data powered by FactSet, Inc. and Morningstar, Inc.

IQVIA Operational KPIs

IQVIA's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.0M for the same period.

IQVIA's Rule of 40 is 29% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

IQVIA's Rule of X is 38% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for IQVIA
LTMLast FY202320242025202620272028
Rule of 4029%29%---
Bessemer Rule of X38%38%---
Revenue per Employee-$0.2M---
Opex per Employee-$0.0M---
Opex to Revenue-19%21%20%19%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Veeva7.6x7.3x16.7x16.1x
GE HealthCare1.8x1.7x9.7x9.9x
Roper Technologies5.7x5.5x14.2x13.9x
Sartorius6.4x6.3x20.9x20.5x
Samsung BioLogics13.6x12.7x22.8x23.3x
Divi's Laboratories16.2x15.8x44.0x48.2x
Wuxi Biologics5.1x4.8x12.5x12.5x
Lonza Group5.8x5.6x18.3x17.7x

This data is available for Pro users. Sign up to see all IQVIA competitors and their valuation data.

Start Free Trial

Acquisitions by IQVIA

IQVIA has acquired 11 companies to date.

Last acquisition by IQVIA was on October 8th 2023. IQVIA acquired OpenApp for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by IQVIA

OpenApp
Pharmaspectra
AllCare Plus Pharmacy
Linguamatics
Description
OpenApp is a Dublin-headquartered software firm specializing in open-source development for healthcare applications. The company delivers patient registry systems, geographic information platforms, health intelligence tools, and document management solutions for medical providers. Clients in Ireland and Europe rely on OpenApp's custom integrations with electronic health records and compliance standards like GDPR and HIQA regulations. Founded in 2005, it employs agile methodologies to build scalable web and mobile apps using technologies such as PostgreSQL, React, and Docker. OpenApp supports public health initiatives through projects with HSE Ireland and private clinics.
Pharmaspectra delivers specialized data analytics and insights for medical affairs teams in pharmaceuticals and biotechnology. Boston-based, the company aggregates real-world evidence from field medical interactions, congress activities, and key opinion leader engagements. Pharmaspectra serves clients like Pfizer and Novartis by generating benchmarks on HCP interactions and publication strategies through its proprietary platform.
AllCare Plus Pharmacy is a specialty pharmacy in Northborough, Massachusetts, specializing in complex medication management for chronic conditions including rheumatoid arthritis, hepatitis C, and oncology. The pharmacy provides 24/7 clinical support, adherence packaging, and compliance programs like prior authorization assistance. Accredited by URAC, it dispenses biologics and infused therapies with delivery services across New England.
Linguamatics is a software provider of natural language processing text mining tools for extracting key facts and relationships from extensive document sets. Its I2E platform supports applications in business intelligence, competitive analysis, life sciences research, and social media monitoring like Twitter. Cambridge-based since 1999, the company serves pharmaceutical firms and intelligence agencies with high-performance querying across unstructured data sources at linguamatics.com.
HQ CountryIrelandUnited StatesUnited StatesUnited Kingdom
HQ City
Dublin
New York City, NY
Worcester, MA
Cambridge
Deal Date8 Oct 20231 Aug 202216 Sep 202012 Feb 2019
Valuationundisclosed$100Mundisclosed$65M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all IQVIA acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by IQVIA

IQVIA has invested in 7 companies to date.

Latest investment by IQVIA was on April 14th 2020. IQVIA invested in ObvioHealth in their $17M Series A round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by IQVIA

ObvioHealth
RxWare
BC Platforms
Octopus.Health
Description
ObvioHealth is a New Jersey-headquartered digital health firm conducting decentralized clinical trials via mobile apps. Participants engage remotely using smartphones for data collection, integrating wearables like Apple Watch and Fitbit. Features include chatbots, video calls, lab scheduling, and PayPal reimbursements, supporting site-less and hybrid studies worldwide.
RxWare is a SaaS provider helping pharmaceutical manufacturers streamline patient access to therapies via the Patient Gateway platform. Founded in 2013, the vendor-neutral system connects ePrescribing platforms, manufacturer hubs, specialty pharmacies, affordability programs, system integrators, and nursing services. RxWare facilitates prior authorizations, benefit verifications, and free trial fulfillment, reducing therapy start times and improving adherence for brands in oncology, rare diseases, and specialty areas.
BC Platforms is a Helsinki-headquartered data technology provider for life sciences and healthcare. Its Data Access Platform enables access to over 22 million life-years of curated patient data, including real-world data, clinical records, genomics, and omics datasets from global partners. The company offers data-as-a-service to pharmaceutical firms like AstraZeneca and Novartis, supporting R&D from discovery to post-market surveillance. Its technology ensures compliance with privacy laws across jurisdictions and integrates with standards like FHIR and GA4GH. BC Platforms also delivers clinical decision-support tools for genomics analysis to healthcare providers worldwide.
Octopus.Health is a Tel Aviv-based patient engagement platform that deploys AI-driven Healthcare Personal Assistants for millions of patients. The technology uses machine learning algorithms to deliver tailored proactive healthcare plans and improve patient adherence. Founded in 2017, the company focuses on population health management through advanced analytics.
HQ CountryUnited StatesUnited StatesSwitzerlandIsrael
HQ City
New York City, NY
Wilmington, DE
Zurich
Tel Aviv
Deal Date14 Apr 202021 Jan 202018 Dec 20191 Oct 2019
RoundSeries ASeries ASeries CSeed
Raised$17M$6M$15M$6M
InvestorsAyala; IQVIA; SPRIM; Tikehau CapitalIQVIA; Windham Venture PartnersDebiopharm Innovation Fund; IQVIA; TesiIQVIA
Valuationundisclosedundisclosedundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all IQVIA investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About IQVIA

When was IQVIA founded?IQVIA was founded in 2016.
Where is IQVIA headquartered?IQVIA is headquartered in United States.
How many employees does IQVIA have?As of today, IQVIA has over 93K employees.
Who is the CEO of IQVIA?IQVIA's CEO is Ari Bousbib.
Is IQVIA publicly listed?Yes, IQVIA is a public company listed on NYSE.
What is the stock symbol of IQVIA?IQVIA trades under IQV ticker.
When did IQVIA go public?IQVIA went public in 2013.
Who are competitors of IQVIA?IQVIA main competitors include Veeva, GE HealthCare, Roper Technologies, Sartorius, Samsung BioLogics, Divi's Laboratories, Wuxi Biologics, Lonza Group, IDEXX Laboratories, Wuxi AppTec.
What is the current market cap of IQVIA?IQVIA's current market cap is $31B.
What is the current revenue of IQVIA?IQVIA's last 12 months revenue is $17B.
What is the current revenue growth of IQVIA?IQVIA revenue growth (NTM/LTM) is 6%.
What is the current EV/Revenue multiple of IQVIA?Current revenue multiple of IQVIA is 2.7x.
What is the current EBITDA of IQVIA?IQVIA's last 12 months EBITDA is $4B.
What is IQVIA's EBITDA margin?IQVIA's last 12 months EBITDA margin is 23%.
What is the current EV/EBITDA multiple of IQVIA?Current EBITDA multiple of IQVIA is 11.6x.
What is the current FCF of IQVIA?IQVIA's last 12 months FCF is $2B.
What is IQVIA's FCF margin?IQVIA's last 12 months FCF margin is 13%.
What is the current EV/FCF multiple of IQVIA?Current FCF multiple of IQVIA is 20.8x.
How many companies IQVIA has acquired to date?As of June 2026, IQVIA has acquired 11 companies.
What was the largest acquisition by IQVIA?$200M acquisition of STI Technologies on 23rd February 2017 was the largest M&A IQVIA has done to date.
What companies IQVIA acquired?IQVIA acquired STI Technologies, Advanced Health Media, Pharmaspectra, Linguamatics, Themis Analytics, AllCare Plus Pharmacy, Polaris, Pilgrim Quality Solutions, OpenApp, Aileron Solutions, and 1 other company.
In how many companies IQVIA has invested to date?As of June 2026, IQVIA has invested in 7 companies.
What was the last IQVIA investment?On 14th April 2020 IQVIA invested in ObvioHealth, participating in a $17M Series A round, alongside Ayala, SPRIM, and Tikehau Capital.
In what companies IQVIA invested in?IQVIA invested in COTA Healthcare, ObvioHealth, BC Platforms, Belong.Life, RxWare, Octopus.Health, and Naxions.

See public comps similar to IQVIA

Lists including IQVIA

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial